SL
LGND icon

Salomon & Ludwin’s Ligand Pharmaceuticals LGND Stock Holding History

Salomon & Ludwin’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.9K Buy
200
+56
+39% +$11.1K ﹤0.01% 614
2025
Q4 		$27.7K Sell
144
-1
-0.7% -$192 ﹤0.01% 660
2025
Q3 		$26.2K Buy
+145
New +$21.6K ﹤0.01% 647

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Salomon & Ludwin's LGND Position: Q1 2026 in Review

Salomon & Ludwin increased its Ligand Pharmaceuticals (LGND) stake by 39% in Q1 2026, buying an estimated $11.1K and bringing the position to 200 shares worth $39.9K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Salomon & Ludwin first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Salomon & Ludwin held 200 shares of Ligand Pharmaceuticals worth $39.9K as of Q1 2026.
  • Salomon & Ludwin bought 56 Ligand Pharmaceuticals shares in Q1 2026, an estimated $11.1K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #614 holding.
  • Salomon & Ludwin first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.